We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMERGO
RNS Number : 3547I
Ergomed plc
02 December 2022
PRESS RELEASE
John Dawson CBE Appointed Senior Independent Director
Guildford, UK - 2 December 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has been appointed Senior Independent Director of the Board with immediate effect. Mr Dawson has served as an independent Non-Executive Director and Chair of the Audit Committee of the Ergomed Board of Directors since March 2022.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanović (Executive Chairman) Richard Barfield (Chief Financial Officer) Keith Byrne (Senior Vice-President, Capital Markets & Strategy) Numis (Nominated Advisor and Joint Broker) Tel: +44 (0) 20 7260 1000 Freddie Barnfield / Euan Brown (Nominated Adviser) James Black (Broker) Peel Hunt LLP (Joint Broker) Tel: +44 (0) 20 7418 James Steel / Dr Christopher Golden 8900 Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700 UK enquiries Chris Gardner / Matthew Neal ergomed@consilium-comms.com Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOATBBBTMTTMTMT
(END) Dow Jones Newswires
December 02, 2022 02:00 ET (07:00 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions